PYC Therapeutics' Blinding Eye Disease Treatment Candidate Gets Orphan Drug Designation in Europe
MT Newswires Live
Apr 27
PYC Therapeutics (ASX:PYC) said its VP-001 drug candidate for blinding eye disease Retinitis Pigmentosa type 11 received orphan drug designation from the European Medicines Agency, according to a Monday filing with the Australian bourse.
The benefits of the designation include scientific advice and other assistance from the European regulator, lower regulatory fees for the drug candidate's review, and 10 years of exclusivity in the European market once approved.
VP-001 previously obtained orphan drug designation and fast track status from the US Food and Drug Administration, PYC Therapeutics said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.